Table 4 Distribution of renal biopsy diagnoses among elderly and younger patients with non-nephrotic range proteinuria
From: Kidney disease in the elderly: biopsy based data from 14 renal centers in Poland
| Â | Non-nephrotic range proteinuria with hematuria | P | Non-nephrotic range proteinuria without hematuria | P | Non-nephrotic range proteinuria with or without hematuria | P | |||
|---|---|---|---|---|---|---|---|---|---|
Renal pathology | ≥65 (n = 76) | 18–64 (n = 787) | ≥65 (n = 58) | 18–64 (n = 328) | ≥65 (n = 134) | 18–64 (n = 1124) | |||
Pauci immune GN  crescentic GN  focal segmental GN | 25 (32.9%) 15 (19.7%) 10 (13.2%) | 92 (11.7%) 52 (6.6%) 40 (5.1%) | <0.001 <0.001 0.009 | 4 (6.9%) 2 (3.5%) 2 (3.5%) | 7 (2.1%) 2 (0.6%) 5 (1.5%) | 0.067 0.109 0.284 | 29 (21.6%) 17 (12.7%) 12 (9.0%) | 99 (8.8%) 54 (4.8%) 45 (4.0%) | <0.001 0.001 0.015 |
IgAN | 15 (19.7%) | 336 (42.7%) | <0.001 | 5 (8.6%) | 74 (22.6%) | 0.013 | 20 (14.9%) | 413 (36.7%) | <0.001 |
FSGS | 11 (14.5%) | 97 (12.3%) | 0.586 | 12 (20.7%) | 65 (19.8%) | 0.860 | 23 (17.2%) | 163 (14.5%) | 0.439 |
Unclassified lesions | 7 (9.2%) | 29 (3.7%) | 0.032 | 3 (5.2%) | 24 (7.3%) | 0.781 | 10 (7.5%) | 53 (4.7%) | 0.204 |
MGN | 4 (5.3%) | 27 (3.4%) | 0.342 | 10 (17.2%) | 40 (12.2%) | 0.292 | 14 (10.5%) | 67 (6.0%) | 0.046 |
LN | 2 (2.6%) | 73 (9.3%) | 0.049 | 2 (3.5%) | 28 (8.5%) | 0.285 | 4 (3.0%) | 102 (9.1%) | 0.013 |
Tubulointerstitial nephritis | 2 (2.6%) | 4 (0.5%) | 0.091 | 4 (6.9%) | 10 (3.1%) | 0.242 | 6 (4.5%) | 16 (1.4%) | 0.023 |
LCDD/HCDD | 2 (2.6%) | 2 (0.3%) | 0.041 | 1 (1.7%) | 1 (0.3%) | 0.278 | 3 (2.2%) | 3 (0.3%) | 0.019 |
Membrano-proliferative GN | 2 (2.6%) | 15 (1.9%) | 0.656 | 0 | 9 (2.7%) | 0.366 | 2 (1.5%) | 24 (2.1%) | 1.000 |
End-stage kidney | 2 (2.6%) | 18 (2.3%) | 0.694 | 2 (3.5%) | 7 (2.1%) | 0.630 | 4 (3%) | 25 (2.2%) | 0.540 |
TBMD | 1 (1.3%) | 23 (2.9%) | 0.715 | 0 | 2 (0.6%) | 1.000 | 1 (0.8%) | 25 (2.2%) | 0.513 |
MCD | 1 (1.3%) | 5 (0.6%) | 0.426 | 4 (6.9%) | 8 (2.4%) | 0.089 | 5 (3.7%) | 13 (1.2%) | 0.035 |
Amyloidosis | 1 (1.3%) | 7 (0.9%) | 0.523 | 8 (13.8%) | 15 (4.6%) | 0.013 | 9 (6.7%) | 23 (2.1%) | 0.005 |
MGA | 0 | 31 (3.9%) | 0.102 | 1 (1.7%) | 16 (4.9%) | 0.281 | 1 (0.8%) | 48 (4.3%) | 0.046 |
DKD | 0 | 8 (1.0%) | 1.000 | 1 (1.7%) | 5 (1.5%) | 1.000 | 1 (0.8%) | 13 (1.2%) | 1.000 |
Thrombotic microangiopathy | 0 | 10 (1.3%) | 1.000 | 1 (1.7%) | 9 (2.7%) | 1.000 | 1 (0.8%) | 20 (1.8%) | 0.718 |
Arterionephrosclerosis | 0 | 2 (0.3%) | 1.000 | 2 (3.5%) | 6 (1.8%) | 0.344 | 2 (1.5%) | 8 (0.7%) | 0.289 |
Normal kidney morphology | 0 | 12 (1.5%) | 0.614 | 0 | 2 (0.6%) | 1.000 | 0 | 14 (1.3%) | 0.385 |
Alport syndrome | 0 | 8 (1.0%) | 1.000 | 0 | 2 (0.6%) | 1.000 | 0 | 10 (0.9%) | 1.000 |